

CITATION REPORT

List of articles citing

Poor compliance with adjuvant chemotherapy use associated with poorer survival in patients with rectal cancer: An NCDB analysis

DOI: 10.1002/encr.30261
Cancer, 2017, 123, 52-61.

Source: <https://exaly.com/paper-pdf/67718802/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
50	Challenges behind proving efficacy of adjuvant chemotherapy after preoperative chemoradiation for rectal cancer. <i>Lancet Oncology, The</i> , 2017 , 18, e354-e363	21.7	57
49	Association Between Adjuvant Chemotherapy and Overall Survival in Patients With Rectal Cancer and Pathological Complete Response After Neoadjuvant Chemotherapy and Resection. <i>JAMA Oncology</i> , 2018 , 4, 930-937	13.4	60
48	Prognostic value of neoadjuvant treatment response in locally advanced rectal cancer. <i>Journal of Surgical Research</i> , 2018 , 226, 15-23	2.5	8
47	Total Neoadjuvant Therapy: A Shifting Paradigm in Locally Advanced Rectal Cancer Management. <i>Clinical Colorectal Cancer</i> , 2018 , 17, 1-12	3.8	62
46	Adjuvant treatment in older patients with rectal cancer: a population-based review. <i>Current Oncology</i> , 2018 , 25, e499-e506	2.8	5
45	Association of Discretionary Hospital Volume Standards for High-risk Cancer Surgery With Patient Outcomes and Access, 2005-2016. <i>JAMA Surgery</i> , 2019 , 154, 1005-1012	5.4	34
44	Adjuvant chemotherapy in rectal cancer patients who achieved a pathological complete response after preoperative chemoradiotherapy: a systematic review and meta-analysis. <i>Scientific Reports</i> , 2019 , 9, 10008	4.9	7
43	Emerging trends in the treatment of rectal cancer. <i>Acta Oncologica</i> , 2019 , 58, 1343-1351	3.2	9
42	Adjuvant chemotherapy in patients with rectal cancer achieving pathologic complete response after neoadjuvant chemoradiation and surgery. <i>European Journal of Cancer</i> , 2019 , 108, 97-99	7.5	4
41	Compliance to Adjuvant Chemotherapy of Patients Who Underwent Surgery for Rectal Cancer: Report from a Multi-institutional Research Network. <i>World Journal of Surgery</i> , 2019 , 43, 2544-2551	3.3	12
40	Comment on Adjuvant chemotherapy in patients with rectal cancer achieving pathologic complete response after neoadjuvant chemoradiation and surgery. <i>European Journal of Cancer</i> , 2019 , 112, 32-33	7.5	
39	Adjuvant Chemotherapy Improves Survival Following Resection of Locally Advanced Rectal Cancer with Pathologic Complete Response. <i>Journal of Gastrointestinal Surgery</i> , 2019 , 23, 1614-1622	3.3	15
38	Is adjuvant chemotherapy necessary for locally advanced rectal cancer patients with pathological complete response after neoadjuvant chemoradiotherapy and radical surgery? A systematic review and meta-analysis. <i>International Journal of Colorectal Disease</i> , 2019 , 34, 113-121	3	20
37	Compliance to treatment guidelines and survival in women undergoing interval debulking surgery for advanced epithelial ovarian cancer. <i>Cancer Reports</i> , 2020 , 3, e1217	1.5	1
36	Association between adjuvant chemotherapy and survival in patients with rectal cancer and pathological complete response after neoadjuvant chemoradiotherapy and resection. <i>British Journal of Cancer</i> , 2020 , 123, 1244-1252	8.7	4
35	Omission of Adjuvant Chemotherapy in Rectal Cancer Patients with Pathologic Complete Response: a National Analysis. <i>Journal of Gastrointestinal Surgery</i> , 2021 , 25, 1857-1865	3.3	2
34	Quality Assurance, Metrics, and Improving Standards in Rectal Cancer Surgery in the United States. <i>Frontiers in Oncology</i> , 2020 , 10, 655	5.3	2

33	Adjuvant Chemotherapy Use in Patients With Locally Advanced Rectal Cancer: A Single-Institution Experience. <i>Clinical Colorectal Cancer</i> , 2020 , 19, e124-e128	3.8	0
32	Management of the positive pathologic circumferential resection margin in rectal cancer: A national cancer database (NCDB) study. <i>European Journal of Surgical Oncology</i> , 2021 , 47, 296-303	3.6	1
31	The treatment-travel tradeoff of colorectal cancer care. <i>Surgery</i> , 2021 , 169, 989-990	3.6	
30	Evaluating the Impact of ESPAC-1 on Shifting the Paradigm of Pancreatic Cancer Treatment. <i>Journal of Surgical Research</i> , 2021 , 259, 442-450	2.5	2
29	Treatment-induced evolutionary dynamics in nonmetastatic locally advanced rectal adenocarcinoma. <i>Advances in Cancer Research</i> , 2021 , 151, 39-67	5.9	0
28	Short-course radiotherapy with consolidation chemotherapy versus conventionally fractionated long-course chemoradiotherapy for locally advanced rectal cancer: randomized clinical trial. <i>British Journal of Surgery</i> , 2021 , 108, 511-520	5.3	7
27	Current evidence regarding the role of adjuvant chemotherapy in rectal cancer patients with pathologic complete response after neoadjuvant chemoradiotherapy: a systematic review and meta-analysis. <i>International Journal of Colorectal Disease</i> , 2021 , 36, 1395-1406	3	
26	Tailored total neoadjuvant therapy for locally advanced rectal cancer: One size may not fit for all!. <i>Colorectal Disease</i> , 2021 , 23, 1662-1669	2.1	0
25	Multidisciplinary management of elderly patients with rectal cancer: recommendations from the SICG (Italian Society of Geriatric Surgery), SIFIPAC (Italian Society of Surgical Pathophysiology), SICE (Italian Society of Endoscopic Surgery and new technologies), and the WSES (World Society of Emergency Surgery) International Consensus Project. <i>World Journal of Emergency Surgery</i> , 2021 , 16, 35	9.2	7
24	Variation in outcomes across surgeons meeting the Leapfrog volume standard for complex oncologic surgery. <i>Cancer</i> , 2021 , 127, 4059-4071	6.4	1
23	Patient Risk Subgroups Predict Benefit of Adjuvant Chemotherapy in Stage II Rectal Cancer Patients Following Neoadjuvant Chemoradiation and Total Mesorectal Excision. <i>Clinical Colorectal Cancer</i> , 2021 , 20, e155-e164	3.8	1
22	Women are predisposed to early dose-limiting toxicities during adjuvant CAPOX for colorectal cancer. <i>International Journal of Clinical Practice</i> , 2021 , 75, e14863	2.9	1
21	Organ preservation in rectal cancer, the desire of a new paradigm. <i>Cirugía Española</i> , 2021 , 100, 389-389	0.7	
20	Colorectal Pathology in the Pelvis. <i>Journal of Gynecologic Surgery</i> , 2021 , 37, 373-379	0.4	
19	Racial Disparities in the Management of Locoregional Colorectal Cancer. <i>Surgical Oncology Clinics of North America</i> , 2022 , 31, 65-79	2.7	0
18	Principles of Adjuvant and Neoadjuvant Therapy for Locally Advanced Rectal Cancer. 2019 , 445-463		
17	Chemotherapy and Biologic Therapy in Rectal Cancer: An Update. 2019 , 407-444		
16	Trimodal Therapy Approaches for Localized Rectal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020 , 18, 954-957	7.3	

15	Survival After Induction Chemotherapy and Chemoradiation Versus Chemoradiation and Adjuvant Chemotherapy for Locally Advanced Rectal Cancer.. <i>Oncologist</i> , 2022 ,	5.7	1
14	Outcomes of rectal cancer patients with a positive pathological circumferential resection margin.. <i>Langenbeck's Archives of Surgery</i> , 2022 , 1	3.4	
13	Organ preservation in rectal cancer, the desire of a new paradigm.. <i>Cirugía Española (English Edition)</i> , 2022 , 100, 389-389	0.1	
12	Red Cell Distribution Width and High Grade Serous Ovarian Cancer: Prognostic Marker?. <i>Indian Journal of Gynecologic Oncology</i> , 2022 , 20,	0.2	
11	An assessment of left-digit bias in the treatment of older patients with potentially curable rectal cancer. <i>Surgery</i> , 2022 ,	3.6	o
10	Total Neoadjuvant Therapy for Rectal Cancer in the CAO/ARO/AIO-12 Randomized Phase 2 Trial: Early Surrogate Endpoints Revisited. 2022 , 14, 3658		o
9	Benefit or bias: Using retrospective databases to evaluate efficacy of cancer treatments. 2022 , 24, 899-903		o
8	Is There a Role for Adjuvant Chemotherapy in Pathologic Node-Negative Locally Advanced Rectal Cancer After Neoadjuvant Chemoradiation Therapy?.		o
7	Clinical and biochemical predictors of tumor response after neoadjuvant therapy in rectal cancer.		o
6	Clinical outcome after total neoadjuvant treatment (CAO/ARO/AIO-12) versus intensified neoadjuvant and adjuvant treatment (CAO/ARO/AIO-04) A comparison between two multicenter randomized phase II/III trials. 2022 , 109455		o
5	Adjuvant chemotherapy and survival outcomes in rectal cancer patients with good response (ypT0-2N0) after neoadjuvant chemoradiotherapy and surgery: A retrospective nationwide analysis. 2022 , 12,		o
4	Clinical significance of adjuvant chemotherapy for pathological complete response rectal cancer patients with acellular mucin pools after neoadjuvant chemoradiotherapy. 2023 , 16, 175628482211178		o
3	Neoadjuvant Immune Checkpoint Inhibitor Therapy for Patients With Microsatellite Instability-High Colorectal Cancer: Shedding Light on the Future.		o
2	Population-Based Analysis of National Comprehensive Cancer Network (NCCN) Guideline Adherence for Patients with Anal Squamous Cell Carcinoma in California. 2023 , 15, 1465		o
1	The value of post-operative chemotherapy after chemoradiotherapy in patients with high-risk locally advanced rectal cancer—Results from the RAPIDO trial. 2023 , 8, 101158		o